

Exhibit 1
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands)

	As of December 31, 2012	As of December 31, 2013
	US\$	US\$
	(Note 1)	(unaudited)
ASSETS		
Current assets:		
Cash and cash equivalents	247,859	385,224
Restricted cash (Note 2)	7,246	759
Restricted investment (Note 2)	14,282	—
Short-term investments	615,003	847,041
Accounts receivable, net	185,701	220,228
Inventories	110,099	138,808
Value added tax receivables	7,427	10,225
Other receivables	15,704	21,512
Prepayments and deposits	11,081	14,310
Deferred tax assets, net	6,443	9,585
Total current assets	1,220,845	1,647,692
Restricted cash, non-current (Note 2)	—	17,453
Other assets	10,811	10,755
Accounts receivables, net, non-current	2,172	1,389
Advances for purchase of plant and equipment	3,009	18,919
Property, plant and equipment, net	268,010	324,710
Land use rights, net	56,921	59,463
Intangible assets, net	132,334	181,077
Goodwill	163,016	242,476
Total assets	1,857,118	2,503,934
LIABILITIES AND EQUITY		
Current liabilities:		
Short-term bank loans	85,100	260,000
Notes payable	8,697	10,945
Accounts payable	53,244	93,673
Advances from customers	17,550	28,240
Salaries payable	69,919	91,220
Other payables	108,528	118,951
Purchase consideration payable	20,354	20,457
Income taxes payable	30,305	20,721
Other taxes payable	8,894	12,832
Total current liabilities	402,591	657,039
Long-term bank loan	50,039	215,703
Other long-term liabilities	4,004	7,222
Deferred tax liabilities, net	23,369	45,812
Total liabilities	480,003	925,776
Commitments and contingencies		
Shareholders' equity:		
Ordinary shares	15	15
Additional paid-in capital	514,280	521,617
Retained earnings	699,992	865,676
Accumulated other comprehensive income	116,556	150,432
Treasury stock at cost	—	(18,792)
Total shareholders' equity	1,330,843	1,518,948
Non-controlling interests	46,272	59,210
Total equity	1,377,115	1,578,158
Total liabilities and equity	1,857,118	2,503,934

- (1) Financial information is extracted from the audited financial statements included in the Company's 2012 annual reports on Form 20-F.
- (2) Restricted cash and restricted investment are mainly those purchase consideration in connection with our acquisition being held on escrow accounts.

Exhibit 2
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except for share and per share data)

	Three months ended December 31,		Year ended December 31,	
	2012	2013	2012	2013
	US\$ (unaudited)	US\$ (unaudited)	US\$ (Note 1)	US\$ (unaudited)
Net revenues				
- <i>China</i>	148,136	160,401	472,991	551,155
- <i>International</i>	167,980	208,014	587,063	662,832
Net revenues	316,116	368,415	1,060,054	1,213,987
Cost of revenues	(133,355)	(162,516)	(459,389)	(527,402)
Gross profit	182,761	205,899	600,665	686,585
Selling expenses	(53,688)	(61,374)	(188,804)	(220,589)
General and administrative expenses	(36,467)	(49,565)	(116,228)	(128,308)
Research and development expenses	(32,926)	(40,990)	(104,302)	(127,464)
Income from operations	59,680	53,970	191,331	210,224
Other income, net	177	3,049	1,619	3,881
Interest income	7,949	10,786	30,794	37,047
Interest expense	(1,028)	(2,160)	(4,093)	(6,345)
Income before income taxes and non-controlling interests	66,778	65,645	219,651	244,807
Income tax (provision) benefits	(9,895)	11,484	(37,369)	(14,260)
Net income	56,883	77,129	182,282	230,547
Less: Net income attributable to non-controlling interests	(1,034)	(1,913)	(2,073)	(5,793)
Net income attributable to the Company	55,849	75,216	180,209	224,754
Basic earnings per share	0.48	0.64	1.54	1.91
Diluted earnings per share	0.47	0.63	1.50	1.87
Shares used in the computation of:				
Basic earnings per share	117,358,594	118,300,560	116,749,213	117,705,414
Diluted earnings per share	120,099,229	120,006,267	119,815,004	120,051,635

(1) Financial information is extracted from the audited financial statements included in the Company's 2012 annual reports on Form 20-F.

Exhibit 3
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands)

	Three months ended December 31,		Year ended December 31,	
	2012	2013	2012	2013
	US\$ (unaudited)	US\$ (unaudited)	US\$ (Note 1)	US\$ (unaudited)
Cash flow from operating activities:				
Net income	56,883	77,129	182,282	230,547
Adjustments to reconcile net income to net cash provided by operating activities	20,057	21,189	69,724	72,293
Changes in assets and liabilities, net of effects of acquisitions	67,953	23,878	73,660	5,078
Net cash provided by operating activities	144,893	122,196	325,666	307,918
Cash flow from investing activities:				
Acquisition cost of subsidiaries, net of cash received	(3,064)	(4,358)	(34,552)	(109,376)
Capital expenditure	(18,361)	(41,901)	(65,605)	(109,080)
(Increase) decrease in restricted cash and restricted investment	(21,528)	356	(21,528)	3,316
Proceeds from sale of short-term investments	—	61,088	144,395	652,896
Increase in short-term investments and changes in other investing activities	(19,727)	(68,152)	(255,255)	(862,297)
Net cash used in investing activities	(62,680)	(52,967)	(232,545)	(424,541)
Cash flow from financing activities:				
Repayment of bank loans	(2,475)	—	(2,475)	(35,000)
Proceeds from bank loans, net of costs	—	156,715	52,000	371,715
Dividend paid	—	—	(46,401)	(59,070)
Proceeds from exercise of options	1,964	491	24,593	16,091
Repurchases of common shares	—	(42,369)	—	(42,369)
Cash contribution from non-controlling interest	—	—	506	—
Net cash (used in) provided by financing activities	(511)	114,837	28,223	251,367
Net increase in cash and cash equivalents	81,702	184,066	121,344	134,744
Cash and cash equivalents, beginning of period	164,499	200,018	124,311	247,859
Effect of exchange rate changes on cash	1,658	1,140	2,204	2,621
Cash and cash equivalents, end of period	247,859	385,224	247,859	385,224

(1) Financial information is extracted from the audited financial statements included in the Company's 2012 annual reports on Form 20-F.

Exhibit 4
MINDRAY MEDICAL INTERNATIONAL LIMITED
RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE
NEAREST COMPARABLE GAAP MEASURES
(Dollars in thousands, except for share and per share data)

	Three months ended December 31,		Year ended December 31,	
	2012	2013	2012	2013
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
	US\$	US\$	US\$	US\$
Non-GAAP net income attributable to the Company	61,658	73,853	211,687	264,073
<i>Non-GAAP net margin</i>	19.5%	20.0%	20.0%	21.8%
Amortization of acquired intangible assets	(3,404)	(3,272)	(8,298)	(13,024)
Reversal (provision) of withholding tax for intra-group fund transfer	—	20,804	—	—
Deferred tax impact related to acquired intangible assets	327	895	504	1,663
Dispute charges, net of related tax impact	—	(13,275)	(9,700)	(13,275)
Share-based compensation	(2,732)	(3,789)	(13,984)	(14,683)
GAAP net income attributable to the Company	55,849	75,216	180,209	224,754
<i>GAAP net margin</i>	17.7%	20.4%	17.0%	18.5%
Non-GAAP basic earnings per share	0.53	0.62	1.81	2.24
Non-GAAP diluted earnings per share	0.51	0.62	1.77	2.20
GAAP basic earnings per share	0.48	0.64	1.54	1.91
GAAP diluted earnings per share	0.47	0.63	1.50	1.87
Shares used in computation of:				
Basic earnings per share	117,358,594	118,300,560	116,749,213	117,705,414
Diluted earnings per share	120,099,229	120,006,267	119,815,004	120,051,635
Non-GAAP operating income	65,816	75,781	223,313	252,681
<i>Non-GAAP operating margin</i>	20.8%	20.6%	21.1%	20.8%
Amortization of acquired intangible assets	(3,404)	(3,272)	(8,298)	(13,024)
Dispute charges	—	(14,750)	(9,700)	(14,750)
Share-based compensation	(2,732)	(3,789)	(13,984)	(14,683)
GAAP operating income	59,680	53,970	191,331	210,224
<i>GAAP operating margin</i>	18.9%	14.6%	18.0%	17.3%
Non-GAAP gross profit	184,799	208,048	606,214	694,689
<i>Non-GAAP gross margin</i>	58.5%	56.5%	57.2%	57.2%
Amortization of acquired intangible assets	(1,849)	(1,937)	(4,738)	(7,352)
Share-based compensation	(189)	(212)	(811)	(752)
GAAP gross profit	182,761	205,899	600,665	686,585
<i>GAAP gross margin</i>	57.8%	55.9%	56.7%	56.6%
Non-GAAP selling expenses	(51,165)	(59,293)	(180,788)	(210,572)
<i>Non-GAAP as % of total revenues</i>	16.2%	16.1%	17.1%	17.3%
Amortization of acquired intangible assets	(1,555)	(1,335)	(3,560)	(5,672)
Share-based compensation	(968)	(746)	(4,456)	(4,345)
GAAP selling expenses	(53,688)	(61,374)	(188,804)	(220,589)
<i>GAAP as % of total revenues</i>	17.0%	16.7%	17.8%	18.2%
Non-GAAP general and administrative expenses	(35,966)	(33,551)	(102,119)	(108,739)
<i>Non-GAAP as % of total revenues</i>	11.4%	9.1%	9.6%	9.0%
Dispute charges	—	(14,750)	(9,700)	(14,750)
Share-based compensation	(501)	(1,264)	(4,409)	(4,819)
GAAP general and administrative expenses	(36,467)	(49,565)	(116,228)	(128,308)
<i>GAAP as % of total revenues</i>	11.5%	13.5%	11.0%	10.6%
Non-GAAP research and development expenses	(31,852)	(39,423)	(99,995)	(122,697)
<i>Non-GAAP as % of total revenues</i>	10.1%	10.7%	9.4%	10.1%
Share-based compensation	(1,074)	(1,567)	(4,307)	(4,767)
GAAP research and development expenses	(32,926)	(40,990)	(104,302)	(127,464)
<i>GAAP as % of total revenues</i>	10.4%	11.1%	9.8%	10.5%

Exhibit 5**MINDRAY MEDICAL INTERNATIONAL LIMITED****RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES,
DEPRECIATION AND AMORTIZATION****(Dollars in thousands)**

	Three months ended		Year ended December 31,	
	December 31,		December 31,	
	2012	2013	2012	2013
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
GAAP net income attributable to the Company	55,849	75,216	180,209	224,754
Interest income	(7,949)	(10,786)	(30,794)	(37,047)
Interest expense	1,028	2,160	4,093	6,345
Income tax provision (benefits)	9,895	(11,484)	37,369	14,260
Earnings before interest and taxes ("EBIT")	58,823	55,106	190,877	208,312
Depreciation	7,445	8,985	28,043	33,499
Amortization	5,606	5,430	14,361	21,079
Earnings before interest, taxes, depreciation, and amortization ("EBITDA")	71,874	69,521	233,281	262,890